Source:http://linkedlifedata.com/resource/pubmed/id/10929022
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2000-8-31
|
| pubmed:abstractText |
We performed a pilot study including rituximab (Mabthera; IDEC-C2B8, Hoffmann-La Roche) with a sequential high-dose therapy protocol in 15 patients with follicular and three patients with mantle cell lymphoma and studied the potential of the chemoimmunotherapy to induce depletion of malignant B cells in vivo. Our treatment protocol included induction with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy, followed by peripheral blood stem cell (PBSC) mobilization using high-dose cytosine arabinoside (2 g/m2 every 12 h, days 1 and 2) and mitoxantrone (10 mg/m2, days 2 and 3) (HAM), preceeded by rituximab (375 mg/m2). The proportion of CD19+ B cells in blood and bone marrow decreased from 1.2 +/- 0.4% to 0.13 +/- 0. 1% (P = 0.01) and from 2.7 +/- 0.8% to 0.8 +/- 0.5% (P = 0.03) respectively. The number of t(14;18)-positive cells in blood and bone marrow progressively decreased with treatment, as assessed by the quantitative real-time PCR assay in four patients. Conversion to PCR-negativity was achieved in the peripheral blood (PB) of seven informative patients. Leucaphereses were performed during the granulocyte colony-stimulating factor (G-CSF)-supported leucocyte recovery phase. In 17 of 18 patients, a median of 15.1 x 106 CD34+ cells/kg body weight (BW) could be harvested by a single procedure for enrichment by an immunomagnetic method. Leucapheresis products contained 51.3 +/- 28.8 x 104 CD19+ B cells/kg BW (mean) and were t(14;18) PCR negative in all seven informative patients. These data compare favourably with results obtained in patients treated with the same regimen without rituximab. The high-dose therapy (n = 12 patients), including total body irradiation (14.4 Gy) and cyclophosphamide (200 mg/kg BW), was also preceeded by rituximab. Recovery of neutrophils to > 0.5 x 109/l and of platelets to > 20 x 109/l required a median of 13.5 and 11.5 d (range 11-24 and 9-24 d) respectively. In conclusion, the addition of the CD20 antibody to chemotherapy ensured tumour depletion in vivo and allowed the collection of PBSCs devoid of tumour cells and with conserved engraftment capability.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mitoxantrone,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0007-1048
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
109
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
729-35
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:10929022-Adult,
pubmed-meshheading:10929022-Antibodies, Monoclonal,
pubmed-meshheading:10929022-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:10929022-Antineoplastic Agents,
pubmed-meshheading:10929022-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10929022-B-Lymphocytes,
pubmed-meshheading:10929022-Combined Modality Therapy,
pubmed-meshheading:10929022-Cyclophosphamide,
pubmed-meshheading:10929022-Cytarabine,
pubmed-meshheading:10929022-Doxorubicin,
pubmed-meshheading:10929022-Female,
pubmed-meshheading:10929022-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10929022-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:10929022-Humans,
pubmed-meshheading:10929022-Immunosuppressive Agents,
pubmed-meshheading:10929022-Leukapheresis,
pubmed-meshheading:10929022-Lymphocyte Depletion,
pubmed-meshheading:10929022-Lymphoma, Follicular,
pubmed-meshheading:10929022-Lymphoma, Mantle-Cell,
pubmed-meshheading:10929022-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10929022-Male,
pubmed-meshheading:10929022-Middle Aged,
pubmed-meshheading:10929022-Mitoxantrone,
pubmed-meshheading:10929022-Pilot Projects,
pubmed-meshheading:10929022-Polymerase Chain Reaction,
pubmed-meshheading:10929022-Prednisone,
pubmed-meshheading:10929022-Transplantation, Autologous,
pubmed-meshheading:10929022-Vincristine,
pubmed-meshheading:10929022-Whole-Body Irradiation
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Department of Internal Medicine V, University of Heidelberg, and German Cancer Research Centre, Heidelberg, Germany. mtvoso@rm.unicatt.it
|
| pubmed:publicationType |
Journal Article
|